Verma Deepshikha, Stapleton Megan, Gadwa Jake, Vongtongsalee Kridakorn, Schenkel Alan R, Chan Edward D, Ordway Diane
Mycobacteria Research Laboratories, Department of Microbiology, Immunology and Pathology, Colorado State University, Fort Collins, CO, United States.
Department of Medicine, Denver Veterans Affairs Medical Center, Denver, CO, United States.
Front Microbiol. 2019 Apr 3;10:693. doi: 10.3389/fmicb.2019.00693. eCollection 2019.
Infections caused by complex (MAC) species are increasing worldwide, resulting in a serious public health problem. Patients with MAC lung disease face an arduous journey of a prolonged multidrug regimen that is often poorly tolerated and associated with relatively poor outcome. Identification of new animal models that demonstrate a similar pulmonary pathology as humans infected with MAC has the potential to significantly advance our understanding of nontuberculosis mycobacteria (NTM) pathogenesis as well as provide a tractable model for screening candidate compounds for therapy. One new mouse model is the C3HeB/FeJ which is similar to MAC patients in that these mice can form foci of necrosis in granulomas. In this study, we evaluated the ability of C3HeB/FeJ mice exposure to an aerosol infection of a rough strain of MAC 2285 to produce a progressive infection resulting in small necrotic foci during granuloma formation. C3HeB/FeJ mice were infected with MAC and demonstrated a progressive lung infection resulting in an increase in bacterial burden peaking around day 40, developed micronecrosis in granulomas and was associated with increased influx of CD4 Th1, Th17, and Treg lymphocytes into the lungs. However, during chronic infection around day 50, the bacterial burden plateaued and was associated with the reduced influx of CD4 Th1, Th17 cells, and increased numbers of Treg lymphocytes and necrotic foci during granuloma formation. These results suggest the C3HeB/FeJ MAC infection mouse model will be an important model to evaluate immune pathogenesis and compound efficacy.
由鸟分枝杆菌复合体(MAC)引起的感染在全球范围内呈上升趋势,导致了严重的公共卫生问题。患有MAC肺病的患者面临着漫长的多药治疗过程,这一过程往往耐受性差且预后相对不佳。识别出能展现出与感染MAC的人类相似肺部病理特征的新动物模型,有可能显著推进我们对非结核分枝杆菌(NTM)发病机制的理解,并为筛选治疗候选化合物提供一个易于处理的模型。一种新的小鼠模型是C3HeB/FeJ,它与MAC患者相似之处在于这些小鼠在肉芽肿中可形成坏死灶。在本研究中,我们评估了C3HeB/FeJ小鼠暴露于MAC 2285粗糙菌株的气溶胶感染后产生进行性感染并在肉芽肿形成过程中导致小坏死灶的能力。C3HeB/FeJ小鼠感染MAC后表现出进行性肺部感染,细菌负荷增加,在第40天左右达到峰值,在肉芽肿中出现微坏死,且与CD4 Th1、Th17和Treg淋巴细胞向肺部的流入增加有关。然而,在第50天左右的慢性感染期间,细菌负荷趋于平稳,与CD4 Th1、Th17细胞的流入减少以及肉芽肿形成过程中Treg淋巴细胞数量增加和坏死灶增多有关。这些结果表明,C3HeB/FeJ MAC感染小鼠模型将是评估免疫发病机制和化合物疗效的重要模型。